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Abstract
It has long been accepted that immunoglobulins (Igs) were produced by B lymphoid cells only. Recently Igs have been
found to be expressed in various human cancer cells and promote tumor growth. Recombination activating gene 1 (RAG1)
and RAG2, which are essential enzymes for initiating variable-diversity-joining segment recombination, have also been
found to be expressed in cancer cells. However, the mechanism of RAG activation in these cancer cells has not been
elucidated. Here, we investigated the regulatory mechanism of RAG expression in four human cancer cell lines by analyzing
transcription factors that induce RAG activation in B cells. By RT-PCR, Western blot and immunofluorescence, we found that
transcription factors E2A, FOXO1 and FOXP1 were expressed and localized to the nuclei of these cancer cells. Over-
expression of E2A, FOXO1 or Foxp1 increased RAG expression, while RNA interference of E2A, FOXO1 or FOXP1 decreased
RAG expression in the cancer cells. Chromatin immunoprecipitation experiments showed acetylation of RAG enhancer
(Erag) and E2A, FOXO1 or FOXP1 were bound to Erag in vivo. These results indicate that in these cancer cells the
transcription factors E2A, FOXO1 and FOXP1 regulate RAG expression, which initiates Ig gene rearrangement much in the
way similar to B lymphocytes.
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Introduction
It has long been accepted that immunoglobulins (Igs) can only be
expressed in mature B lymphocytes and plasma cells. However,
recently several groups reported that Igs could also be produced by
non-lymphoid lineage cells [1], including human cancer cells [2,3],
soft tissue tumor cells [4], neurons and glial cells of the central and
peripheral nervous system [5], ocular epithelial and ganglion cells
[6], mouse testicular spermatogenic cells and epididymal epithelial
cells [7] and mouse lactating mammary gland epithelial cells [8].
Most of the research has thus far focused on Ig expression in cancer
cells.TheRecombinationactivatinggene(RAG)hasalsobeenfound
expressed in cancer cells both at the mRNA and the protein levels
and it is assumed to play a significant role in the synthesis of Igs by
these cancer cells [2,3,9]. However, the regulatory mechanism of
RAG expression in cancer cells has not yet been determined.
The variable regions of Ig genes are composed of one variable
(V), one diversity (D), and one joining (J) gene segment, the
arrangement of which results from V(D)J recombination [10]. RAG
endonuclease is required for the initiation of the cleavage phase of
V(D)J recombination [11]. RAG consists of two adjacent genes,
RAG1 and RAG2, that synergistically induce V(D)J recombination
[12]. Previous studies have shown that mice deficient in either
RAG1 or RAG2 failed to initiate V(D)J rearrangement [13,14].
RAG1 and RAG2 proteins together were found to be sufficient to
cleave recombination substrates in cell free systems [15,16]. In
murine B cell development RAG expression occurs in two waves
and is regulated by a network of transcription factors, including
E2A, Ikaros, Pax5b, Foxo1, Foxp1, and NF-kB [17]. The first wave
results in the rearrangement of the immunoglobulin heavy chain in
pro-B cells. And the second wave of RAG expression leads to the
assembly of immunoglobulin light chain in pre-B cells.
In addition to the RAG1 and RAG2 promoters, the RAG gene
has also other regulatory elements, such as the proximal enhancer
(Ep), the distal enhancer (Ed) and the RAG enhancer (Erag)
[17,18,19,20,21,22]. It is thought that the aforementioned
transcription factors regulate RAG expression by binding to their
corresponding regulatory sequences in B cells. Erag is the strongest
enhancer regulating RAG expression. Targeted deletion of Erag in
the mouse germline resulted in a 5-fold to 10-fold decrease in
RAG expression and a partial block at the pro-B to pre-B
transition [22]. E2A, Ikaros, Foxo1, Foxp1 and NF-kB were all
shown to activate RAG expression by binding to Erag in murine B
cells [22,23,24,25,26]. Pax5b was reported to activate RAG2
promoter in immature B cells [27]. Whether these transcription
factors are also expressed in cancer cells and whether they have
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worthy of investigation.
In this study, we first analyzed the protein and mRNA
expressions of those transcription factors that have been found to
be essential for RAG activation in B cells, including E2A (E47 and
E12), FOXO1, FOXP1, Ikaros, NF-kB, and PAX5b, in four cancer
cell lines. We then studied the localization of a number of these
transcription factors (E2A, FOXP1, NF-kB and FOXO1) by
immunofluorescence (IF). We found that E2A, FOXO1 and
FOXP1 were expressed in cancer cells and localized to the nuclei
of these cells. Over-expression of these three transcription factors
significantly increased RAG expression. Functional inactivation of
the genes of any of these three transcription factors by RNA
interference decreased RAG expression. In vivo chromatin
immunoprecipitation (ChIP) assay showed that the histone H3 of
Eragwas acetylatedandthat E2A, FOXO1, FOXP1werebound to
Erag in these cancer cells. These results indicate that transcription
factors E2A, FOXO1 and FOXP1 activate the expression of RAG,
which is critical for V(D)J recombination, in cancer.
Materials and Methods
Ethics statement
We didn’t use any human or animal tissues in our study. So we
didn’t feel that ethics approval was necessary.
Cell culture
The human lung cancer cell line A549, prostate cancer cell line
PC3, breast cancer cell lines MCF-7, MDA-MB-231 and Burkitt
lymphoma cell line Raji were obtained from the American Type
Culture Collection (ATCC). A549, PC3, MCF-7 and MDA-MB-
231 cells were cultured in Dulbecco’s Modified Eagle’s Medium
(DMEM) with 10% FBS (Hyclone/Thermo Fisher Scientific Inc.,
Waltham, MA). Raji cells were cultured in RPMI 1640
(Invitrogen, Carlsbad, CA) with 10% FBS at 37uC in a humidified
atmosphere with 5% CO2.
RNA extraction and RT-PCR
Total RNA was extracted from the tumor cells using Trizol
reagent (Invitrogen, Carlsbad, CA) and treated with RNase Free
DNase (Invitrogen) to remove genomic DNA. Reverse transcrip-
tion of the RNA was performed using the Superscript
TM III First
Strand Synthesis System (Invitrogen, Carlsbad, CA) following the
manufacturer’s instructions. For the negative control, the reverse
transcriptase was not added to the reaction mixture. Conventional
or nested PCR was performed and the primers used in this study
were listed in Table 1. For Ikaros, which has several different
isoforms, nested PCR was used to increase the sensitivity and to
better characterize the specific Ikaros isoforms [28]. The two
isoforms of E2A, E47 and E12 were both amplified by PCR.
Table 1. Oligonucleotides used in this study.
Gene name RT-PCR primers Primer sequence 5’-3’ product size (bp)
Ikaros External sense primer CACATAACCTGAGGACCATG 255-945
External antisense primer AGGGCTTTAGCTCATGTGGA
Internal sense primer ATGGATGCTGATGAGGGTCAAGAC
Internal antisense primer GATGGCTTGGTCCATCACGTGG
PAX5b Sense primer CCCGATGGAAATACACTGTAAGCAC 203
Antisense primer TTTTGCTGACACAACCATGGCTGAC
P65 Sense primer TCAATGGCTACACAGGACCA 308
Antisense primer CACTGTCACCTGGAAGCAGA
E47 Sense primer AGCAGTACGGACGAGGTGCTGTCCCTGG 162
Antisense primer CGCTTTGTCCGACTTGAGGTGCAT
E12 Sense primer ACCAGCCCAGACGAGGACGAGGACGACC 173
Antisense primer GGGCTTCTCGCTGTTGAGGTGCAG
FOXO1 Sense primer GCAGATCTACGAGTGGATGGTC 325
Antisense primer AAACTGTGATCCAGGGCTGTC
FOXP1 Sense primer TCAGTGGTAACCCTTCCCTTA 255
Antisense primer GTACAGGATGCACGGCTTG
18S Sense primer AAACGGCTACCACATCCAAG 155
Antisense primer CCTCCAATGGATCCTCGTTA
RNAi sequence
E2A GGCGCAGUUCGGAGGUUCATT
FOXP1 GCAGCAAGUUAGUGGAUUATT
FOXO1 GCCCUGGCUCUCACAGCAATT
ChIP PCR primers
Erag1 Sense primer GCACTGCAAATGGCCTGTGAAC 197
Antisense primer TAGAGACCAGAGGGCTTAACATT
Erag3 Sense primer AAGCCTCTCTTTGCACCCTCAT 201
Antisense primer TTGAGTTGTCATTTCAGCCAAA
doi:10.1371/journal.pone.0020475.t001
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Cell lysates were prepared using RIPA buffer. About 40 mgo f
total cellular protein was separated on 5% to 10% SDS-PAGE gel.
After electrophoresis, the separated proteins were transferred to a
polyvinylidene difluoride membrane. The primary antibodies used
included RAG1 (K-20), RAG2 (D-20), GAPDH (0411), E2A
(Yae), FOXP1 (D35D10), NF-kB p65 (F-6), and FOXO1 (H-128).
FOXP1 antibody was obtained from Cell Signaling Technology
and the other antibodies were purchased from Santa Cruz
Biotechnology. After incubation with the secondary antibodies
(goat anti-mouse IgG-HRP or goat anti-rabbit IgG-HRP, Santa
Cruz), the immunoblots were developed using Super ECL Plus
Detection Reagent (Applygen Technologies, Beijing) and exposed
to X-ray film according to the manufacturer’s protocol.
Immunofluorescence
Cells were grown on slides in 6 well plates and fixed in 4%
paraformaldehyde for 15 min at room temperature. Then the
slides were incubated with 0.5% Triton X-100 for 10 min, and
blocked for 1 hour in PBS containing 4% bovine serum albumin
(BSA). The primary antibodies included E2A (Yae), FOXP1
(D35D10), NF-kB p65 (F-6) and FOXO1 (H-128). The detailed
information for these antibodies were shown in table 2. Isotype
controls were performed using normal mouse or rabbit IgG at the
same concentration as the primary antibodies. After incubation at
4uC overnight and washing, the slides were incubated with the
secondary antibody goat anti-mouse IgG-FITC (green signal) or
goat anti-rabbit IgG-TRITC (red signal) at room temperature for
1 hour. After a final wash, slides were mounted with mounting
media with DAPI (Vector Laboratories, Burlingame, CA) and
examined under a fluorescence microscope (Carl Zeiss).
Plasmids construction and transfection
The human E47 and E12 fragments were cloned into a pIRES2-
EGFP plasmid by restriction enzyme Bgl II and EcoR I from
plasmids MigR1-hE47 and MigR1-hE12, respectively, which were
kind gifts from Dr. Barbara Kee of the University of Chicago. The
pCDNAI/NEO-5’HA-Foxp1A plasmid which encoded murine
Foxp1A protein was generously provided by Dr. Philip Tucker of
the University of Texas at Austin [29]. The FOXP1 protein was
veryconservedbetweenhumanand murinespecies(morethan90%
identities), so we used this plasmid for our study. The pcDNA3-
GFP-FOXO1;AAA plasmid was obtained from Addgene and it was
prepared in Dr. William Sellers’ laboratory as described previously
[30]. This plasmid contained a phosphosite mutation of FOXO1,
which as a result hereof was no longer phosphorylated by Akt and
could still localize to the nucleus and activate transcription in
Figure 1. Gene transcript expression of Ikaros, PAX5b, NF-kB,
E2A, FOXO1 and FOXP1 in cancer cell lines. 18S was used as an
internal control. Raji was used as a positive control. DNase treated RNA
without adding reverse transcriptase was used as a negative control.
doi:10.1371/journal.pone.0020475.g001
Figure 2. Western blot showing NF-kB p65, E2A, FOXO1,
FOXP1, RAG expression in epithelial cancer cells. Raji cell was
used as a positive control. GAPDH was used as an internal control.
doi:10.1371/journal.pone.0020475.g002
Table 2. Antibodies for immunofluorescence.
Primary antibody Type Concentration or dilution Manufacturer
E2A (Yae) Mouse, monoclonal 4 mg/ml Santa Cruz Biotechnology, CA, USA
FOXO1 (H-128) Rabbit, polyclonal 4 mg/ml Santa Cruz Biotechnology, CA, USA
FOXP1 (D35D10) Rabbit, monoclonal 1:50 Cell Signaling Technology, MA, USA
NF-kB p65 (F-6) Mouse, monoclonal 4 mg/ml Santa Cruz Biotechnology, CA, USA
doi:10.1371/journal.pone.0020475.t002
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MCF-7 cancer cells were done using Fugene HD Transfection
Reagent (Roche) according to the manufacturer’s instructions.
RNA interference
Small interfering RNA (siRNA) directed against FOXO1 [32],
FOXP1, E2A and nonspecific control siRNA (GenePharma, Shang-
hai, China) were transfected into A549 and MCF-7 cancer cells using
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s
instructions. The siRNA sequences were listed in Table 1.
ChIP
Chromatincrosslinkingandimmunoprecipitationwereperformed
as described previously [23]. The anti-acetyl-histone H3 (06-599,
Upstate Biotechnology), E2A (Yae), E47 (N-649), FOXP1 (D35D10)
or FOXO1 (H-128) was used. Both the E2A (Yae) and E47 (N-649)
antibody were used in ChIP for E2A. Normal rabbit IgG (sc-2027,
Santa Cruz) or normal mouse IgG (sc-2025, Santa Cruz) was used as
a negative control. Immunoprecipitated DNA sequences were
analyzed with PCR and the primers were listed in Table 1.
Results
E2A, FOXO1, FOXP1 and NF-kB were expressed in cancer
cell lines
RT-PCR results showed that FOXO1, FOXP1, NF-kB subunit
p65 and both of the two isoforms of E2A (E47 and E12), were
expressed in the cancer cells A549, PC3, MCF-7 and MDA-MB-
231 (Figure 1). However, neither Ikaros nor PAX5b was detected
in these cancer cell lines, whereas they could both be amplified
from Raji cells. At the protein level, E2A, FOXO1, FOXP1 and
NF-kB subunit p65 were all detected in the cancer cells with
Western blot assay (Figure 2). Based on the molecular weight, the
full length FOXP1 was found to be the main isoform of FOXP1
expressed in the cancer cells. We also confirmed the expression of
RAG1 and RAG2 in these cancer cell lines (Figure 2).
E2A, FOXO1 and FOXP1 were localized to the nuclei of
cancer cells
To study the localization of E2A, FOXO1, FOXP1 and NF-kB
in cancer cells, IF was performed using the corresponding
antibodies on the four cancer cell lines. The results showed that
E2A and FOXP1 were predominantly localized to the nucleus,
whereas NF-kB was exclusively localized to the cytoplasm of the
cancer cells (Figure 3). FOXO1 was found to translocate between
the nucleus and cytoplasm, with the location depending on the
culture and growth conditions. When the cells were confluent,
FOXO1 was mainly located in the nucleus, while it was mainly
present in the cytoplasm when the cells were sparse. Since
transcription factors need to be localized in the nucleus in order to
regulate gene expression, we just focused on E2A, FOXO1 and
FOXP1 in the second part of our study.
Over-expression of E2A, FOXO1 or Foxp1 up-regulated
RAG expression
To explore the effect of transcription factors E2A, FOXO1 and
FOXP1 on RAG expression, A549 and MCF-7 cells were
transfected with the expression vector for E47, E12, Foxp1A or
FOXO1. The empty vector was used as a negative control. Forty-
eight hours after transfection, total protein was extracted for
analysis of E2A, FOXP1, FOXO1 and RAG expression by
Western blot assay. The results showed that transfection with the
expression vector for E47, E12, Foxp1A or FOXO1 increased
both RAG1 and RAG2 expressions (Figure 4). This data indicate
that over-expression of E2A, FOXO1 or Foxp1 up-regulated the
expression of RAG1 and RAG2 in MCF-7 cells. Similar results
were obtained using the A549 cell line (data not shown).
RNA interference of E2A, FOXO1 or FOXP1 down-
regulated RAG expression
To further study the regulatory function of E2A, FOXO1 and
FOXP1 on the expression of RAG, the siRNA sequences for E2A,
FOXO1 or FOXP1 were transfected into A549 and MCF-7 cells.
The nonspecific siRNA was used as the negative control. 48 hours
after transfection, total protein was extracted for analyzing E2A,
FOXP1, FOXO1 and RAG expression by Western blot assay.
Transfection with siRNA sequence for E2A, FOXP1 or FOXO1
was found to decrease the expressions of both RAG1 and RAG2
(Figure 5), suggesting that silencing E2A, FOXO1 or FOXP1
genes down-regulates RAG1 and RAG2 expressions in MCF-7
Figure 3. Immunofluorescence showing NF-kB p65, E2A, FOXO1 and FOXP1 localization in the MCF-7 cell line. A, normal mouse IgG
was used instead of the primary antibody. B, the primary antibody was mouse anti-E2A. C, the primary antibody was mouse anti-NF-kB p65. A to C,
the secondary antibody was goat anti-mouse IgG-FITC. D, normal rabbit IgG was used instead of the primary antibody. E, the primary antibody was
rabbit anti-FOXO1. F, the primary antibody was rabbit anti-FOXP1. D to F, the secondary antibody was goat anti-rabbit IgG-TRITC. Similar results were
obtained for the A549, PC3 and MDA-MB-231 cell lines (data not shown).
doi:10.1371/journal.pone.0020475.g003
Figure 4. Transient over-expression of E47, E12, FOXO1 or
Foxp1A increased RAG expression in MCF-7 cells. MCF-7 cells
were transfected with the empty vector or transcription factor
expression vector pIRES2-EGFP-hE47, pIRES2-EGFP-hE12, pcDNA3-GFP-
FOXO1;AAA or pCDNAI/NEO-5’HA-Foxp1A. 48 hours later total protein
from MCF-7 cells was collected and analyzed by Western blot. GAPDH
was shown as a loading control. Experiments were repeated three times
with similar results. Similar results were obtained for the A549 cell line
(data not shown).
doi:10.1371/journal.pone.0020475.g004
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(data not shown).
E2A, FOXO1 and FOXP1 bound to Erag in vivo
In murine B cells transcription factors E2A, Foxo1 and Foxp1
regulate RAG expression through binding to Erag, the enhancer
regulating RAG gene expression. In order to investigate whether
these transcription factors behave similarly in cancer cells, ChIP
was performed on A549 and MCF-7 cells. The Erag region 1
contains three binding sites for E2A and one binding site for
FOXO1 or FOXP1, whereas the Erag region 3 contains no
binding site for E2A and one binding site for FOXO1 or FOXP1
[25]. ChIP results showed that histone H3 of both Erag region 1
and 3 was acetylated, indicating that Erag was in an open or
activated state. In addition, transcription factors E2A, FOXO1
and FOXP1 were demonstrated to be bound to Erag region 1
but not to region 3 (Figure 6). For both cell lines similar results
were obtained.
Discussion
Recently several research groups reported that V(D)J recombi-
nation and RAG expression occurred in cancer cells. However,
the mechanism controlling these phenomena in epithelial cells is
currently unknown. In this study, in analogy with the molecular
mechanism of RAG expression in B cells, we explored the
regulatory mechanism of RAG expression in cancer cells by
analyzing the transcription factors E2A, Ikaros, PAX5b, FOXO1,
FOXP1 and NF-kB. Similar to their role in the activation of RAG
expression in B cells, we found that E2A, FOXO1 and FOXP1
regulated RAG expression in cancer cells by binding to Erag.
E2A belongs to the class I helix-loop-helix (HLH) proteins, also
known as E proteins because of their capacity to bind with relative
high affinity to the palindromic DNA sequence CANNTG,
referred to as an E box site [33,34]. The E2A gene encodes for
two E proteins, E12 and E47, which arise through alternative
splicing of the exon encoding for the HLH domain [35]. E12 and
E47 are primary transcription activators that function, in part, by
recruiting the co-activator protein p300/CBP, which in turn
recruits histone acetyltransferases and RNA polymerase II to the
promoter or enhancers of target genes [36,37]. E2A is believed to
be a key regulator of B cell differentiation by activating the
expression of RAG and other B lymphoid genes [34]. Over-
expression of E47 has previously been found to activate RAG1
expression and IgH germ-line transcription in fibroblasts [38].
Ectopic expression of E2A, together with RAG1 and RAG2
promoted both IgH and IgL gene rearrangements in a non-
lymphoid embryonic kidney cell line [39,40]. Our finding that
both RAG and E2A proteins were expressed in cancer cells
contributes to the understanding of the mechanism of V(D)J
recombination in neoplastic cells.
FOXO1 and FOXP1 belong to the family of Forkhead box
proteins, which contain a common DNA-binding domain (DBD)
termed the forkhead box or winged helix domain [41]. FOXO1
can translocate from the nucleus to the cytoplasm after being
phosphorylated by Akt. Murine Foxp1 has four alternatively
spliced isoforms, Foxp1A–Foxp1D [29]. Deregulation of FOXO1
and FOXP1 had been shown in many cancer types [41,42].
Recently two studies showed that Foxo1 and Foxp1 regulated
RAG expression in murine B cells [24,25]. Here we have shown
Figure 6. ChIP results showed histone H3 acetylation and E2A,
FOXO1, FOXP1 binding of Erag in MCF-7. A, cross-linked
chromatin isolated from MCF-7 cells was immunoprecipitated either
with isotype control IgG or anti-acetyl-histone H3 antibody. The
associated chromosomal DNA fragments were amplified with primers
for Erag region 1 and 3. B, the antibody for the immunoprecipitation
was anti-E2A, FOXO1 or FOXP1. Experiments were repeated three times
with similar results. Similar results were obtained for A549 cell line (data
not shown).
doi:10.1371/journal.pone.0020475.g006
Figure 5. RNA interference of E2A, FOXO1 or FOXP1 decreased
RAG expression in MCF-7 cells. MCF-7 cells were transfected with
nonspecific control siRNA or siRNA sequence for E2A, FOXO1 or FOXP1.
48 hours later total protein from MCF-7 cells was collected and
analyzed by Western blot. GAPDH was shown as a loading control.
Experiments were repeated three times with similar results. Similar
results were obtained for the A549 cell line (data not shown).
doi:10.1371/journal.pone.0020475.g005
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expression in cancer cells.
In this study, we focused on a selected number of transcription
factors and found that E2A, FOXO1 and FOXP1 regulated RAG
expression in cancer cells. Whether there are additional transcrip-
tion factors involved in RAG expression remains to be explored.
In addition, whether there are more similarities in gene expression
between B cells and cancer cells could be found using high
throughput techniques. Previously, it was reported that Ig
expression promoted tumor growth and progression [2,43,44].
In view of our results on regulatory factors activating RAG
expression, Ig expression in cancer cells might be controlled by
targeting the upstream transcription factors to eventually prevent
tumor progression.
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